Industry-Leading Results Position ALZ-801 to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease Robust Disease-Modifying Effects Observed Through 52 Weeks of Treatment with ALZ-801 Tablet in APOE4 Carriers with Early Alzheimer’s Disease New Data Further Validate Alzheon … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Wet Age-Related Macular Degeneration – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Wet Age-related Macular Degeneration pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “HR Positive/ Her2 Negative Breast Cancer – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering. This “HR Positive/ HER2 Negative Breast Cancer – Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It covers the pipeline … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$QNCX–Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today confirmed that it received an unsolicited offer to acquire the company from Echo Lake Capital. Quince’s Board of Directors, consistent with its fiduciary responsibilities, will carefully review and evaluate the … [Read more…]

TOKYO–(BUSINESS WIRE)–#Biotech—DIC Corporation (DIC) announced the start of joint business development in the area of polyphenols with California-based biotech startup Debut, a vertically integrated synthetic biology company at the forefront of advanced biomanufacturing technology. The polyphenols will be produced using an innovative biotechnology for use in the cosmetics and nutrition industries. As a first step, … [Read more…]

The Company has reached a debt restructuring agreement with its lenders and is finalizing the documentation of the transaction LYON, France–(BUSINESS WIRE)–Regulatory News: POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that … [Read more…]

Leading Medical Center in Israel Leverages YonaLink’s SaaS Platform to Accelerate Innovation and Drive Greater Speed, Quality, and Efficiency in Local and Global Clinical Trial Data Collection BOSTON–(BUSINESS WIRE)–#clinicalresearch–YonaLink, a clinical trial software provider, today announced its EHR-to-EDC data integration platform has been implemented by Hadassah Medical Organization (HMO) in Jerusalem. Recognized worldwide for setting … [Read more…]

  SEOUL, South Korea–(BUSINESS WIRE)–#COEX–The Ministry of Health and Welfare (MOHW) and the Korea Health Industry Development Institute (KHIDI) will host Medical Korea 2023 – The 13th Global Healthcare & Medical Tourism Conference at Coex in Seoul from March 23 (Thu) to March 24 (Fri), 2023. The conference will be held as a large-scale offline … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#chronicpain–Presidio Medical, Inc., a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, announced that Scott Salys joined the Executive Team as Chief Research & Development and Operations Officer. Mr. Salys is a 25-year veteran in Class III active implantable devices leading R&D, Operations, Supply Chain, Program … [Read more…]

– Patient enrollment ongoing in the CALM Phase 3 program with topline data expected for CALM-1 in the second half of 2024 – – Ended year with US$337.1 million in cash, cash equivalents and short-term investments; cash runway extends to the second half of 2025 and through expected topline results of both CALM-1 and CALM-2 … [Read more…]